[go: up one dir, main page]

ATE429916T1 - Verwendung von sulfonamid-derivaten bei der behandlung von adipositas oder zur verringerung der nahrungsaufnahme - Google Patents

Verwendung von sulfonamid-derivaten bei der behandlung von adipositas oder zur verringerung der nahrungsaufnahme

Info

Publication number
ATE429916T1
ATE429916T1 AT02783922T AT02783922T ATE429916T1 AT E429916 T1 ATE429916 T1 AT E429916T1 AT 02783922 T AT02783922 T AT 02783922T AT 02783922 T AT02783922 T AT 02783922T AT E429916 T1 ATE429916 T1 AT E429916T1
Authority
AT
Austria
Prior art keywords
food consumption
treating obesity
sulfonamide derivatives
reducing food
treatment
Prior art date
Application number
AT02783922T
Other languages
English (en)
Inventor
Patrizia Caldirola
Original Assignee
Biovitrum Ab Publ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0103767A external-priority patent/SE0103767D0/xx
Application filed by Biovitrum Ab Publ filed Critical Biovitrum Ab Publ
Application granted granted Critical
Publication of ATE429916T1 publication Critical patent/ATE429916T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • General Preparation And Processing Of Foods (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT02783922T 2001-11-09 2002-11-06 Verwendung von sulfonamid-derivaten bei der behandlung von adipositas oder zur verringerung der nahrungsaufnahme ATE429916T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0103767A SE0103767D0 (sv) 2001-11-09 2001-11-09 New use
US35689002P 2002-02-13 2002-02-13
PCT/SE2002/002019 WO2003039547A1 (en) 2001-11-09 2002-11-06 Use of sulfonamide derivatives in the treatment of obesity or for the reduction of food intake

Publications (1)

Publication Number Publication Date
ATE429916T1 true ATE429916T1 (de) 2009-05-15

Family

ID=26655592

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02783922T ATE429916T1 (de) 2001-11-09 2002-11-06 Verwendung von sulfonamid-derivaten bei der behandlung von adipositas oder zur verringerung der nahrungsaufnahme

Country Status (6)

Country Link
US (1) US20030166663A1 (de)
EP (1) EP1450806B1 (de)
JP (1) JP2005511594A (de)
AT (1) ATE429916T1 (de)
DE (1) DE60232173D1 (de)
WO (1) WO2003039547A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1897876A3 (de) * 2002-06-20 2009-03-18 Biovitrum AB (publ) Zur Behandlung von Obesitas, Typ II-Diabetes und ZNS-Erkrankungen geeignete Verbindungen
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
ES2228268B1 (es) * 2003-07-30 2006-07-01 Laboratorios Del Dr. Esteve, S.A. Combinacion de sustancias activas conteniendo al menos un compuesto con afinidad por el receptor del neuropeptido y (npy) y al menos un compuesto con afinidad por el receptor 5-ht6.
ES2228267B1 (es) * 2003-07-30 2006-07-01 Laboratorios Del Dr. Esteve, S.A. Combinacion de sustancias activas conteniendo al menos un compuesto con afinidad por el receptor del neuropeptido y (npy) y al menos un compuesto con afinidad por el receptor 5-ht6.
EP2305352A1 (de) 2004-04-02 2011-04-06 Merck Sharp & Dohme Corp. 5-alpha-Reduktaseinhibitoren zur Behandlung von Stoffwechsel- und anthropometrischen Störungen
WO2006047302A1 (en) * 2004-10-21 2006-05-04 Transtech Pharma, Inc. Bissulfonamide compounds as agonists of galr1, compositions, and methods of use
US20100105657A1 (en) * 2005-07-05 2010-04-29 Astrazeneca Ab Compounds, Process for their Preparation, Intermediates, Pharmaceutical Compositions and their use in the Treatment of 5-HT6 Mediated Disorders such as Alzheimer's Disease, Cognitive Disorders, Cognitive Impairment Associated with Schizophrenia, Obesity and Parkinson's Disease
WO2007004960A1 (en) * 2005-07-05 2007-01-11 Astrazeneca Ab New compounds, process for their preparation, intermediates, pharmaceutical compositions and their use in the treatment of 5-ht6 mediated disorders such as alzheimer’s desease, cognitive disorders, cognitive impairment associated with schizophrenia, obesity and parkinson’s disease
JP4434182B2 (ja) 2006-07-25 2010-03-17 セイコーエプソン株式会社 眼鏡レンズの設計方法
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
CA3089569C (en) 2007-06-04 2023-12-05 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2009149279A2 (en) 2008-06-04 2009-12-10 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2010009319A2 (en) 2008-07-16 2010-01-21 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
EP3366698A1 (de) 2011-03-01 2018-08-29 Synergy Pharmaceuticals Inc. Guanylat-cyclase-c-agonisten
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
JP2016514671A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
ES2981866T3 (es) 2013-06-05 2024-10-10 Bausch Health Ireland Ltd Agonistas ultrapuros de guanilato ciclasa C, método de elaboración y uso de los mismos

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2810236B2 (ja) 1993-03-16 1998-10-15 フアイザー・インコーポレイテツド ナフタレン誘導体
DZ2376A1 (fr) * 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
GB9803411D0 (en) * 1998-02-18 1998-04-15 Smithkline Beecham Plc Novel compounds
AU2790999A (en) * 1998-03-03 1999-09-20 Merck & Co., Inc. Fused piperidine substituted arylsulfonamides as beta3-agonists
TWI222450B (en) * 1999-07-28 2004-10-21 Upjohn Co Oxazinocarbazoles for the treatment of CNS diseases
GB9926302D0 (en) 1999-11-05 2000-01-12 Smithkline Beecham Plc Novel compounds
US6399617B1 (en) * 2000-07-21 2002-06-04 Biovitrum Ab Use

Also Published As

Publication number Publication date
JP2005511594A (ja) 2005-04-28
EP1450806B1 (de) 2009-04-29
WO2003039547A1 (en) 2003-05-15
DE60232173D1 (de) 2009-06-10
EP1450806A1 (de) 2004-09-01
US20030166663A1 (en) 2003-09-04

Similar Documents

Publication Publication Date Title
ATE429916T1 (de) Verwendung von sulfonamid-derivaten bei der behandlung von adipositas oder zur verringerung der nahrungsaufnahme
ATE353646T1 (de) Verwendung von indol- und indolin-derivaten bei der behandlung von adipositas oder zur reduzierung der nahrungsaufnahme
TW200510334A (en) Preraration and use of aryl alkyl acid derivatives for the treatment of obesity
ATE388951T1 (de) Dpp-iv-inhibierende purin-derivative zur behandlung von diabetes
NO20065079L (no) Materialer og metoder for behandling av koaguleringssykdommer
DE602006010442D1 (de) Verwendung von benzokondensierten heterocyclischen sulfamid-derivaten zur behandlung von schmerzen
EA200802329A1 (ru) Производные триазола ii
DE502004006619D1 (de) Substituierte 2-aminotetraline zur vorbeugenden behandlung von morbus parkinson
DE602006020775D1 (de) Verwendung von benzokondensierten heterocyclischen sulfamid-derivaten zur behandlung von manie und bipolaren störungen
ATE373474T1 (de) Substituierte 2-aminotetraline zur behandlung von depressionen
MY145823A (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity
TW200634012A (en) 3-amino-pyrazolo[3,4b]pyridines as inhibitors of protein tyrosine kinases, their production and use as pharmaceutical agents
MXPA05011203A (es) Fenacil-2-hidroxi-3-diaminoalcanos.
ATE464895T1 (de) Verwendung von benzokondensierten heterocyclischen sulfamid-derivaten zur behandlung von depressionen
BR0309342A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
ATE384058T1 (de) Thiazolderivate
DE602004017481D1 (de) Zur behandlung von schmerzen geeignete therapeutische mittel
BRPI0416030A (pt) pirido-7-pirimidin-7-onas substituìdas com hidroxialquila
ATE267597T1 (de) Verwendung von polycyclischen 2-amino-thiazol systemen zur herstellung von medikamenten zur prophylaxe oder behandlung von obesitas
SE0002739D0 (sv) New use
DE602005014632D1 (de) Pyrrol- bzw. imidazolamide zur behandlung von obesitas
MXPA05007715A (es) Derivados de carboxamida y uso de los mismos como inhibidores del factor xa.
DE602004024871D1 (de) Polyamin-verbindungen zur behandlung von chemokin-rezeptor-vermittelten krankheiten
ATE350034T1 (de) Verwendung von epothilone zur behandlung hyperparathyreoidismus
ATE423780T1 (de) Makrozyclen zur behandlung von krebserkrankungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties